MedPath

Testosterone for HIV-Positive Men With Reduced Serum Testosterone Levels and Abdominal Fat

Phase 4
Completed
Conditions
HIV Infections
Registration Number
NCT00009555
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Brief Summary

The purpose of this study is to see if treatment with testosterone will reduce abdominal fat in HIV-positive men.

Many HIV patients on antiretroviral therapy show an increase in abdominal fat. Studies have shown that treatment with testosterone may decrease abdominal fat. This study will determine if testosterone will reduce abdominal fat in HIV patients.

Detailed Description

Reports suggest that many HIV-infected patients on antiretroviral therapy experience an increase in abdominal fat. The mechanisms of abdominal fat accumulation in HIV-infected patients are not known. Studies have shown: treatment with testosterone gel reduces total body fat in young, androgen-deficient men; testosterone replacement in middle-aged men with mid-segment obesity decreases visceral fat; and replacement doses of testosterone decrease fat mass and augment lean body mass in HIV-infected men with androgen deficiency. Therefore, there is a strong rationale for evaluating the effectiveness of testosterone replacement in HIV-infected men with visceral obesity and low testosterone levels.

Patients are stratified based on their viral load. Patients receive either testosterone gel or placebo applied to the skin once daily for 24 weeks. Patients remain on their current antiretroviral regimens, which are not supplied through the study. Patients who receive testosterone during the first 24 weeks are eligible to receive it for an additional 24 weeks. Patients on placebo are followed for an additional 24 weeks. Clinical and laboratory evaluations for visceral fat changes are performed throughout the study.

Recruitment & Eligibility

Status
COMPLETED
Sex
Male
Target Recruitment
86
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (27)

USC CRS

🇺🇸

Los Angeles, California, United States

Charles R. Drew Univ. of Medicine and Science, Div. of Infectious Diseases

🇺🇸

Los Angeles, California, United States

Stanford CRS

🇺🇸

Palo Alto, California, United States

Ucsd, Avrc Crs

🇺🇸

San Diego, California, United States

Ucsf Aids Crs

🇺🇸

San Francisco, California, United States

Santa Clara Valley Med. Ctr.

🇺🇸

San Jose, California, United States

San Mateo County AIDS Program

🇺🇸

San Mateo, California, United States

Marin County Dept. of Health & Human Services, HIV/AIDS Program & Specialty Clinic

🇺🇸

San Rafael, California, United States

University of Colorado Hospital CRS

🇺🇸

Aurora, Colorado, United States

Queens Med. Ctr.

🇺🇸

Honolulu, Hawaii, United States

Scroll for more (17 remaining)
USC CRS
🇺🇸Los Angeles, California, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.